Over the past several years, significant evidence implicating p21l"-like small GTP-binding proteins in the mechanisms driving membrane-trafficking pathways has been obtained (for reviews, see references 1, 23, and 36) . In particular, the subfamily of Rab proteins appears to participate in vesicle targeting or fusion events. The cycling of these proteins between the inactive (GDP bound) and active (GTP bound) states is believed to catalyze docking to specific target membranes. Thus, in the sec4 mutant yeast strain, the fusion of secretory vesicles to the plasma membranes is perturbed (27) ; antibodies against Rabl and its yeast homolog, YPT1, block transport between the endoplasmic reticulum and Golgi complex (24, 26, 31) ; anti-Rab5 antibodies block early endosome fusion (13) ; and antisense oligonucleotides against Rab3B inhibit Ca-2-dependent exocytosis (18) .
Three types of factors that regulate the interactions of guanine nucleotides with the various Rab proteins have been described: GTPase activating proteins, found for p25r3A (4) and YPT1 (3), accelerate their intrinsic GTPase activity and presumably catalyze their deactivation in vivo; GDP dissociation stimulators increase release of GDP from p25t""3A (5) and the yeast counterparts SEC4 and YPT1 (20) , allowing their reactivation by binding to GTP; and GDP dissociation inhibitor (GDI) inhibits the release of GDP from Rab proteins and plays a role in the recycling of the Rab proteins from target to donor membrane vesicles (30, 37) . These regulatory proteins, together with others now being identified, such as rabphilin (32) , are thought to compose a complex cellular system for coordinating membrane trafficking.
Two GDI proteins have been identified for members of the Rab subfamily (30, 37) . One interacts with almost all of the Rab proteins tested (29, 34, 38) , while the other interacts with Rabll (also designated 24K [37] ) but not Rab3A (also designated smig p25A [30] ). The former GDI cDNA has been cloned from bovine brain, and its mRNA has been detected in all tissues studied (19) . It is also present in secretory cells with both regulated and constitutive secretion pathways (22) , where it is found predominantly in the cytosol complexed with small GTP-binding proteins (25, 34) . Initial attempts to identify a yeast counterpart of GDI with the bovine cDNA as a probe under low-stringency conditions have not yet been successful (29) . These findings indicate that GDI proteins are important modulators of GDP/GTP exchange reactions involving Rab proteins and are potential candidates for regulation by cellular signaling mechanisms.
Insulin stimulation of glucose uptake in fat and skeletal muscle involves the redistribution of a major glucose transporter isoform, GLUT4, from trans-Golgi or endosomal tubulovesicular organelles to the plasma membrane (for a review, see reference 9). Recent studies indicate that insulin modulates both the exocytosis and endocytosis pathways of GLUT4 protein trafficking in fat cells (8, 16, 40) . Several considerations suggest that Rab proteins may also be involved in the membrane movements of GLUT4 transporter proteins. The expression of a novel Rab protein (Rab3D) appears to be associated with differentiation of 3T3-L1 fibroblasts to insulin-responsive cells (2) . Furthermore, the redistribution of Rab4 protein from fat cell low-density microsomes to the cytosol in response to insulin has recently been observed (7) .
To investigate the presence of GDI proteins in insulinsensitive tissues, we screened a mouse skeletal muscle cDNA library for cDNA species encoding GDI proteins. We have isolated a full-length cDNA encoding a novel GDI isoform (mGDI-2) as well as a cDNA encoding the nearly complete amino acid sequence of the GDI previously cloned from bovine brain (mGDI-1). The mRNA and protein levels of both GDI species were found to increase markedly upon differentiation of 3T3-L1 fibroblasts and L6 myoblasts to insulinsensitive adipocytes and myocytes, respectively. Moreover, the recombinant GDI-1 and GDI-2 proteins were able to modulate the membrane association of Rab4 and Rab5 proteins. These findings raise the possibility that GDI proteins may be involved in insulin-regulated membrane recycling of glucose transporters. (14) . Briefly, fibroblasts were grown to confluence (150-mm plate) in DMEM containing 10% calf serum, penicillin (50 U/ml), and streptomycin sulfate (50 pLg/ml). Differentiation was induced with DMEM supplemented with 10% fetal bovine serum, penicillin (50 U/ml), streptomycin sulfate (50 p.g/ml), insulin (5 ,ug/ml), 0.25 FxM dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine. On the second day, the medium was replaced with DMEM containing all but the last two of the above components. Thereafter, the cells were maintained in DMEM containing 10% fetal bovine serum and the antibiotics, with medium changes every 2 to 3 days. COS-7 cells were grown (100-mm plate) in DMEM containing 10% fetal bovine serum and the above antibiotics. rGDI cloning. The coding region of rat GDI (rGDI) was cloned by PCR from single-stranded cDNA from rat brain. PCR was performed with oligonucleotides with the sequences CTGACCATGGACGAGGA(A,G)TA(C,T)A and CGCG GATCCTACTGGTCAGCTTCCCC(G,A)AA(G,A,C)AC (parentheses indicate redundant positions) as described before (39) . The with the full-length rat brain cDNA for GDI described above.
MATERIALS AND METHODS
The procedure was essentially that of Strauss (35) . A total of 800,000 PFU were plated on the C600 Hfl strain of Escherichia coli as the host (Clontech). The plaques were transferred onto nitrocellulose filters (Millipore), alkali denatured, and fixed for 2 h at 80°C in a vacuum oven. The cDNA probe was 32p labeled by random priming (10) . The filters were hybridized in 6x SSC (1 x SSC is 150 mM NaCl, 15 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mg of bacitracin per ml, 5 jig of aprotinin per ml, and 5 ,ug of leupeptin per ml by sonication for 2 min and centrifuged at 12,000 x g for 25 min.
The supernatant was applied to glutathione-agarose beads (Sigma) that were extensively washed with 50 mM Tris-HCl (pH 8.0) containing 0.05% Triton X-100. The GST-GDI-1 and GST-GDI-2 fusion proteins were eluted with the same buffer containing 5 mM glutathione, which was then removed by repeating ultrafiltration in a Centricon 30 microconcentration unit (Amicon). Epitope tagging and transient-expression assay. The fulllength rGDI-1 cDNA (1.4 kbp) was tagged in the NH2 terminus with a nine-amino-acid epitope, YPYDVPDYA, derived from influenza virus hemagglutinin (HA) (11) . Oligonucleotides encoding the sequence detailed above after the initial Met tailed with convenient restriction sites on the ends (5', XbaI; 3', NcoI) were used. The double-stranded oligonucleotide was inserted into an Xbal-NcoI digest of pET8c-rGDI-1 cDNA. The HA-GDI-1 cDNA fragment was subcloned into mammalian expression vector pCMV5 (cloning sites, XbaI and BamHI). The new vector, HA-rGDI-1 pCMV5, was confirmed by sequencing. The full-length mGDI-2 was tagged in the NH2 terminus with an 11-amino-acid epitope, EQKLISEEDLN, derived from the human c-myc proto-oncogene product (21) . Oligonucleotides encoding the sequence detailed above after the initial Met tailed with convenient restriction sites (PstI and EcoRI) were used. The doublestranded oligonucleotide was ligated into a PstI-EcoRI digest of pBluescript-mGDI-2 cDNA that lacked the 5' noncoding region of cloned mGDI-2 (deleted by PCR as described above). The vector pBluescript-c-myc-mGDI-2 was confirmed by sequence analysis. The PstI-SalI c-myc-mGDI-2 cDNA fragment was further subcloned into the PstI-SalI digest of pCMV5.
COS-7 cells were seeded at 750,000 cells per 100-mm plate, and transfection of HA epitope-tagged rGDI-1 and c-Myc epitope-tagged mGDI-2 cDNAs was performed by the calcium phosphate precipitation method as described before (12) . Cell lysates were analyzed by Western blotting (immunoblotting) 48 h later.
In vitro dissociation assay. COS-7 cells (serum starved for 5 h before the experiment) were washed twice before homogenization at 4°C in 20 mM HEPES buffer (pH 7.4) containing 1 mM EDTA, 250 mM sucrose, 1 mM PMSF, 5 jig of leupeptin per ml, and S jig of aprotinin per ml. Equal amounts (120 ,ug of protein) of postnuclear membrane fraction (two sequential centrifugations [10 min at 800 x g and 15 min at 200,000 x g] in a Beckman TL-100 Ultracentrifuge) were incubated for 30 min at 30°C in the presence or absence of the GST-GDI-1 or GST-GDI-2 fusion protein or GST alone (each at 1 jiM) in a reaction buffer consisting of 50 mM HEPES-KOH (pH 7.6), 5 mM MgCl2, 1 mM dithiothreitol, 1 mM PMSF, 5 jig of aprotinin per ml, S jig of leupeptin per ml, and 1 jig of pepstatin per ml. Where indicated, the membranes were preincubated for 45 min at 30°C with GTPyS or GDP (each at 1 mM). The reaction mixtures were pelleted for 10 min at 200,000 x g, and the membranes and the soluble fractions were analyzed for Rab4 and RabS content by fractionation by SDS-polyacrylamide gel electrophoresis (PAGE; 10.5% polyacrylamide gel) and Western blotting with affinity-purified anti-Rab4 antibodies (generously provided by Ira Mellman) and affinity-purified monoclonal anti-RabS antibodies (generously provided by Marino Zerial) under the conditions described below.
Cell lysis, cell fractionation, and immunoblotting. Transfected COS-7 cells were washed twice with ice-cold phosphatebuffered saline (PBS) prior to lysis with 1 ml of lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 1 mM PMSF, 0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40). Lysates were incubated for 5 min on ice and clarified by centrifugation for 15 min at 16,000 x g. Equal amounts of total protein, as measured by the bicinchoninic acid protein assay reagent (Pierce), were fractionated by SDS-PAGE, transferred to nitrocellulose, and blotted with anti-c-Myc monoclonal antibody, anti-HA monoclonal antibody, anti-mGDI-1 peptide antiserum, or anti-mGDI-2 peptide antiserum under conditions described elsewhere (33) . Antibodies were detected by enhanced chemiluminescence (Amersham).
For studying the relative amounts of mGDI-1 and mGDI-2 proteins in 3T3-L1 mouse fibroblasts and differentiated adipocytes, the cells were first homogenized at 4°C in 20 mM HEPES buffer (pH 7.4) containing 1 mM EDTA, 250 mM sucrose, 1 mM PMSF, 5 jig of leupeptin per ml, and 5 jig of aprotinin per ml. Cytosol fractions were obtained as described above and analyzed by immunoblotting.
Antibodies. Rabbit polyclonal anti-GDI-1 and anti-GDI-2 antibodies are directed against an mGDI-1 peptide (amino acids 431 to 447) and an mGDI-2 peptide (amino acids 386 to 404), respectively. The peptides were coupled via an aminoterminal tyrosine to keyhole limpet hemocyanin. Antisera were used at a dilution of 1:14,000 for immunoblotting. Mouse monoclonal antibody 12CA5 (BAbCO), reactive with the influenza virus HA epitope YPYDVPDYA (11), was used to detect epitope-tagged HA-rGDI-1. Mouse monoclonal antibody ATCC 1729, reactive with the epitope EQKLISEEDLN (21) derived from the c-myc proto-oncogene product, was used to detect epitope-tagged c-Myc-mGDI-2.
RESULTS AND DISCUSSION
Isolation and nucleotide sequence analysis of mGDI-1 and mGDI-2 cDNAs. To isolate cDNA clones encoding GDI proteins expressed in muscle, we screened a mouse skeletal muscle cDNA library with a probe corresponding to the entire coding region of rat brain GDI under conditions of moderate stringency. Seven recombinant plaques were found to be strongly positive. One clone (pG4) exhibited weak hybridization to this probe, suggesting that it may have been derived from a new GDI-related gene. All eight recombinant plaques were purified, and their EcoRI inserts (ranging in size from 1.3 to 3.7 kbp) were subcloned into pBluescript vectors. The resulting plasmids were sequenced either directly or after further appropriate restrictions and subcloning into pBluescript. Figure 1 shows the nucleotide sequence of the pG4 clone, designated mGDI-2. This mGDI-2 cDNA is about 2.4 kbp long and contains an open reading frame encoding 445 amino acids flanked by approximately 500 nucleotides on the 5' as well as the 3' sides. The predicted ATG initiation codon conforms well with the canonical sequence for the mammalian translation initiation start site proposed by Kozak (17) . Moreover, the presence of an in-frame terminator upstream of this MOL. CELL. BIOL. mGDI-1 mGDI-1 CGACGCTTCCGAAAATTTTTGGTGTTTGTGGCAAACTTTGATGAGAATGA ** ** *** ******* **** * *** ** ************** ** 155 ProArgThrPheGl uGlyIleAspProLysLysThrSerMetArgGl u mGDI-2 TCCTCGAACTTTTGAGGGCATTGATCCTAAGAAGACATCAATGCGAGAGG 511 mGDI-1 CCCCAAAACCTTTGAGGGTGTTGATCCCCAGAACACCAGCATGCGTGATG ** *** ******** ******* **** ** ***** ** * 171 Val TyrLysLysPheAspLeuGlyGlnAspVa l IleAspPheThrGlyHi s mGDI-2 TGTATAAGAAATTTGACTTGGGCCAAGATGTTATAGATTTTACTGGTCAT 561 mGDI-1 TCTACCGGAAGTTTGACCTGGGTCAAGATGTCATAGATTTCACTGGCCAT * ** *** ****** **** ******** ******** ***** *** 188 AlaLeuAl aLeuTyrArgThrAspAspTyrLeuAspGlnProCysCysGl u mGDI-2 GCCCTGGCACTTTACAGAACTGATGACTATTTAGATCAGCCATGTTGTGA 611 mGDI-1 GCCTTGGCGCTCTACCGCACTGATGAGTACCTGGATCAGCCCTGTCTTGA *** **** ** *** * ******** ** * ******** *** *** ***** * * ***** ** ***** ** ** *********** ***** 255 IleGluGluIleIleMetGlnAsnGlyLysValIleGlyValLysSer mGDI-2 AATTGAAGAAATCATTATGCAAAATGGAAAGGTGATTGGTGTAAAATCTG 811 mGDI-1 AGTGGATGACATCATCATGGAAAATGGCAAGGTGGTGGGTGTCAAATCTG * * ** ** ***** *** ******* ****** * ***** ******* 27 lGluGlyGluIleAlaArgCysLysGlnLeuIleCysAspProSerTyrVal mGDI-2 AAGGAGAGATTGCTCGCTGTAAGCAGCTCATCTGCGATCCCAGCTATGTG 861 mGDI-1 AGGGAGAGGTGGCCCGCTGCAAGCAGCTGATCTGTGATCCCAGTTACATC * ****** * ** ***** ******** ***** ******** ** * 288 LysAspArgVal Gl uLysValGlyGlnVal IleArgVal IleCysIleLeu mGDI-2 AAAGATCGAGTAGAAAAAGTGGGCCAGGTGATCAGAGTCATCTGTATTCT 911 mGDI-1 CCAGACCGTGTGCAAAAGGCTGGCCAGGTTATTCGCATCATCTGTATCCT *** ** ** **** * ******** ** * ********** ** 305 SerHisProlleLysAsn ThrAsnAspAlaAsnSerCysGln IleIle mGDI-2 CAGCCACCCCATCAAAAACACCAATGACGCCAACTCCTGCCAGATCATTA 961 mGDI-1 CAGCCACCCCATCAAGAATACCAATGATGCCAATTCCTGCCAAATTATCA *************** ** ******** ***** ******** ** ** * TCCTCTGCACACAATGTGGCCGCACAAGGCAAGTACATCGCCATTGCCAG 1061 mGDI-1 TCCTATGCGCACAACGTGGCCGCACAGGGCAAATACATCGCCATTGCCAG **** *** ***** *********** ***** ***************** 355 ThrThrValGluThrLysGluProGluLysGluIleArgProAlaLeu mGDI-2 CACAACGGTGGAGACCAAGGAGCCCGAGAAGGAAATCAGACCAGCCCTGG 1111 mGDI-1 CACCACTGTAGAGACTGCAGAACCAGAAAAGGAAGTTGAGCCTGCATTGG *** ** ** ***** ** ** ** ****** * ** ** *** 37lGluLeuLeuGluProIleGluGlnLysPheValSerIleSerAspLeuLeu mGDI-2 AGCTTTTGGAACCAATTGAGCAGAAATTCGTTAGCATCAGTGACCTCCTT 1161 mGDI-1 AGCTGTTGGAACCCATTGACCAGAAGTTTGTGGCTATCAGTGATTTATAT **** ******** ***** ***** ** ** ******** * * 388 ValProLysAspLeuGlyThrGluSerGlnIlePhelleSerArgThrTyr mGDI-2 GTACCAAAAGACTTGGGAACAGAAAGCCAGATCTTTATATCCCGTACCTA 1211 mGDI-1 GAGCCCATTGATGATGGTTCAGAGAGTCAGGTGTTCTGTTCCTGCTCCTA * ** * ** ** **** ** *** * ** *** * **** 405 AspAlaThrThrHisPheGl uThrThrCysAspAspIleLysAspIle mGDI-2 TGATGCAACAACTCACTTTGAGACGACCTGTGATGACATTAAGGACATCT 1261 mGDI-1 TGATGCTACCACACACTTTGAGACAACCTGCAATGACATCAAAGATATCT ****** ** ** *********** ***** ******* ** ** **** 421 TyrLysArgMetMetGlySerGl uPheAspPheGl uGl uMetLysArgLys mGDI-2 ATAAGAGGATGATGGGATCCGAGTTTGACTTTGAGGAAATGAAGCGCAAG 1311 mGDI-1 ACAAACGCATGGCTGGTTCTGCCTTTGATTTTGAGAACATGAAGCGCAAA * ** * *** ** ** * ***** ****** * *********** (19) , rat brain GDI-1, and mouse skeletal muscle GDI-1 and GDI-2. Identical residues are denoted by colons, and replacements are indicated by the corresponding residue (one-letter code). The missing first 124 amino acids of mGDI-1 are marked by dashes.
*---------H---------------------------------------
ATG (TAG, nucleotides -60 to -58) supports the concept that this codon represents the translation initiator of the GDI-2 gene product. The nucleotide sequence of the coding region of the mGDI-2 cDNA is 72% identical to the bovine brain smg p25A GDI (19) (Fig. 1) .
Among the other clones isolated in this study was a 1.3-kbp clone found to contain an open reading frame encoding 969 nucleotides and ending in a TGA stop codon, followed by approximately 300 nucleotides in the 3' noncoding region (Fig.  1) . The nucleotide sequence of the coding region of this cDNA clone, designated mGDI-1, is 90% identical to that for the bovine brain smg p25A GDI. However, this cDNA for mGDI-1 lacked the first 372 nucleotides of the predicted ATG translation start site of the smg p25A GDI. Nevertheless, the high degree of homology between mGDI-1 and the bovine GDI indicates that we have cloned a bovine brain smg p25A GDI homolog from the mouse muscle library.
The comparison of the nucleotide sequences of mGDI-1 and mGDI-2 presented in Fig. 1 -l (1.3 kbp, lanes 1 and 3) and mGDI-2 (2.4 kbp, lanes 2 and 4) cDNA inserts were electrophoresed on a 1 % agarose gel, transferred to nitrocellulose, and hybridized sequentially with the same radiolabeled cDNA inserts under high-stringency conditions. Lanes 1 and 2, radiolabeled mGDI-l as a probe; lanes 3 and 4, radiolabeled mGDI-2 as a probe. and mGDI-2 and rGDI-1 is 85.7, 86.7, and 86.1 %, respectively. When conservative substitutions are eliminated, the sequence similarities are 93.5, 93.8, and 93.1%, respectively. The degree of sequence identity between mGDI-1 and smg p25A GDI and between mGDI-1 and rGDI-1 is 98.1% in both cases. Interestingly, many of the nonconservative substitutions between mGDI-1 and mGDI-2 are concentrated in the C-terminal region of the proteins.
Northern blot analysis of various tissues and insulinresponsive cells. Previous studies have shown that smg p25A GDI message is predominantly expressed in rat brain, although it was also found in all other tissues tested (19) . To analyze whether the newly discovered mGDI-2 is specific for muscle, we attempted to perform Northern blot analysis of various human tissues. Since both GDI forms were found to recognize mRNA transcripts of similar size (2.4 kb), pilot experiments were performed to determine the conditions that eliminate cross-hybridization. Figure 3 shows that under hybridization conditions of relatively high stringency, this could be achieved by using the radiolabeled 1.3-kbp mGDI-1 and 2.4-kbp mGDI-2 cDNA isolates as probes. These conditions were thus used for the Northern blot analysis.
Northern blots of mRNA prepared from various human tissues probed with radiolabeled mGDI-1 and mGDI-2 cDNAs are depicted in Fig. 4 . This analysis revealed that GDI-2 mRNA was highly abundant not only in skeletal muscle but also in lung (highest level), brain, and placenta. To a lesser extent, the GDI-2 transcript was also detected in the other tissues investigated, including heart, kidney, pancreas, and liver. Brain, skeletal muscle, placenta, and liver also expressed GDI-1 mRNA at levels apparently similar to those of GDI-2. In contrast, kidney expressed predominantly GDI-1 mRNA, while in human lung tissue, GDI-2 was the predominant transcript present (Fig. 4) .
The level of GDI-1 and GDI-2 mRNA species present in 3T3-L1 mouse cells and L6 rat cells was also determined by Northern blot analysis. The cultured cell lines differentiate from relatively insulin-unresponsive fibroblasts to highly insulin-sensitive adipocytes and myocytes, respectively. After differentiation, these cells express the GLUT4 glucose transporter protein and exhibit insulin-mediated GLUT4 redistribution to the cell surface membrane (9) . Both GDI-1 and GDI-2 transcripts were observed upon Northern blot analysis of mRNA derived from L6 and 3T3-L1 fibroblasts (Fig. 5) . After differentiation, the levels of both GDI-1 and GDI-2 mRNA species increased relative to the level of f-actin mRNA present (7-fold and 3-fold, respectively, in L6 myocytes; 10-fold and 5-fold, respectively, in 3T3-L1 adipocytes) (Fig. 5) . These data suggest that significant amounts of both GDI protein isoforms exist in these cell lines and that the amounts of these proteins increase in the fully differentiated, insulin-responsive state.
Detection of endogenous and epitope-tagged GDI-1 and GDI-2 proteins. In order to detect GDI proteins, we developed specific antibodies against unique peptide sequences in mGDI-1 and mGDI-2. Anti-GDI-1 antibodies were directed against residues 431 to 447 in the C terminus of mGDI-1 and recognized a major endogenous protein in COS-7 cell lysates that appeared on SDS-PAGE as an apparent 55-kDa protein band (Fig. 6, lane 3) . Transient expression of the HA epitopetagged rGDI-1 in some cells resulted in the appearance of a 57-kDa band in a similar analysis (Fig. 6, lane 1) . The anti-GDI-1 peptide antiserum did not cross-react with the endogenous GDI-2 but did recognize the higher amounts of protein obtained by transiently overexpressing a c-Myc-tagged mGDI-2 construct (apparent 48-kDa band, Fig. 6, lane 2) . Anti-GDI-2 antibodies directed against a peptide sequence that is divergent between the two isoforms (residues 386 to 404 in the C-terminal region) detected a protein with an apparent molecular mass of 46 kDa that migrated slightly faster than the overexpressed c-Myc-mGDI-2 (Fig. 6, lane 5) . Neither the endogenous nor the expressed epitope-tagged rGDI-1 isoform was detected by anti-GDI-2 antibodies (Fig. 6, lanes 4 and 5) . It is interesting that although both forms of GDI have deduced molecular weights of about 51,000, the apparent molecular masses determined by SDS-PAGE are 55 and 46 kDa for GDI-1 and GDI-2, respectively.
The specific anti-GDI-1 and anti-GDI-2 antisera described above were used to test whether increased GDI protein levels are associated with 3T3-L1 cell differentiation, as suggested by the data shown in Fig. 5 . Cytosolic fractions obtained from cultured 3T3-L1 fibroblasts and differentiated 3T3-L1 adipocytes were analyzed by SDS-PAGE and Western blotting with the antisera. As depicted in Fig. 7 , the concentrations of immunoreactive mGDI-1 and mGDI-2 proteins were elevated approximately nine-and threefold, respectively, in the cultured adipocytes compared with their levels in fibroblasts. These data indicate that the acquired insulin sensitivity of 3T3-L1 adipocytes is associated with marked increases in GDI protein levels. Further data will be required to determine whether these or other GDI proteins play a direct role in the altered membrane trafficking of glucose transporters in response to insulin in these cells.
GST-GDI-2 modulates membrane association of Rab proteins. Several studies have demonstrated that bovine brain GDI releases membrane-associated Rab proteins (25, 34, 38 The close similarity between the sequences of mGDI-1 and mGDI-2 indicates that the novel isoform may fulfill similar functions. To address this question, we first generated a recombinant GST-GDI-2 fusion protein. The electrophoretic mobility of this expressed fusion protein (molecular weight, 75,000; not shown) corresponded well to the apparent molecular mass of GST plus mGDI-2 as determined by SDS-PAGE (see Fig. 6 ).
The ability of GST-GDI-2 to remove Rab4 protein from membranes was assessed. As shown in Fig. 8 3) . In contrast, after incubation of membranes with the recombinant GST-GDI-2 protein (1 plM), Rab4 was readily detected in the soluble fraction (Fig. 8, lane 6) . GDP (1 mM) only slightly augmented this membrane dissociation of Rab4, while GTP-yS abrogated it (Fig. 8, lanes 4 and 5) . Since Rab4 in membranes is presumably already in the GDP-bound form, this result indicates that, similar to bovine brain GDI, GDI-2 binds to the GDP-bound form of the Rab protein in membranes and releases it into the soluble fraction. Under the conditions used in these experiments, the capacity of our GST-GDI-2 fusion protein at 1 p.M to solubilize Rab4 amounted to -15 to 20% of the total membrane-associated Rab4 (Fig. 6 , lane 5 versus lane 1).
We next assessed the relative specificities of GDI-2 and GDI-1 for extracting two members of the Rab family, Rab4 and Rab5, from membranes. We first generated a recombinant GST-GDI-1 fusion protein with an electrophoretic mobility (apparent molecular weight, 80,000; not shown) corresponding well to the apparent molecular mass of GST plus as judged by SDS-PAGE (see Fig. 6 ). Similar to GST-GDI-2, GST-GDI-1 was able to extract membrane-associated Rab4 into the soluble fraction (Fig. 8, lane 7) . GST-GDI-1 at a concentration of 1 F.M solubilized an amount of total membrane-associated Rab4 similar to that solubilized by GST-GDI-2 in three separate experiments.
The ability of both fusion proteins to dissociate membranebound RabS was also compared. As shown in Fig. 9 , both recombinant GDI isoforms were able to solubilize immunore- active Rab5 when incubated with COS-7 cell membranes (lanes 2 and 5). This effect was inhibited by GTPyS (Fig. 9 , lanes 4 and 7) and only slightly enhanced by GDP, probably because of the predominance of GDP-bound RabS already present in the membranes. These data suggest that both rGDI-1 and mGDI-2 can function as regulatory proteins for Rab4 and Rab5. However, we cannot conclude from these experiments that subtle differences in the regulation of Rab4 and Rab5 proteins by GDI-1 versus GDI-2 are not also physiologically important.
An important extension of the above experiments will be to test the possibility that one or more of the other Rab proteins are uniquely regulated by only one of the two GDI isoforms studied here. This important question will be challenging to address because of the large number of unique Rab protein candidates to be screened. There is precedence for such specificity. The purified form of the GDI for Rabl I does not interact with Rab3A (37) . The significant variations in the amino acid sequences of GDI-1 and GDI-2, especially in the C-terminal region, could serve as the basis for Rab-binding specificity. However, other properties could also differ between the two proteins, such as cellular localization, regulated phosphorylation, or other posttranslational modifications.
In summary, we have identified and characterized a novel isoform of mammalian GDI that releases membrane-bound Rab4 and RabS proteins and is widely expressed in primary tissues and in insulin-responsive cultured cells. Thus, at least two gene products in murine tissues carry out the functions of GDI proteins in regulating membrane trafficking. It will be of interest to determine whether important differences in function characterize the two GDI isoforms described here. The cloning of the cDNA encoding the novel GDI-2 protein should facilitate efforts to answer this question.
